Cargando…
Antipsychotics dosage and antiparkinsonian prescriptions
BACKGROUND: To study the link between the dosage of several antipsychotics and the prescription of antiparkinsonians in an observational study. METHODS: In the context of a national naturalistic prospective observational study, a database containing all the prescriptions from 100 French psychiatrist...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014748/ https://www.ncbi.nlm.nih.gov/pubmed/17767708 http://dx.doi.org/10.1186/1745-0179-3-14 |
_version_ | 1782136559054618624 |
---|---|
author | Acquaviva, Eric Gasquet, Isabelle Falissard, Bruno |
author_facet | Acquaviva, Eric Gasquet, Isabelle Falissard, Bruno |
author_sort | Acquaviva, Eric |
collection | PubMed |
description | BACKGROUND: To study the link between the dosage of several antipsychotics and the prescription of antiparkinsonians in an observational study. METHODS: In the context of a national naturalistic prospective observational study, a database containing all the prescriptions from 100 French psychiatrists during the year 2002 was analysed. The inclusion criteria were a diagnosis of schizophrenia or schizoaffective disorder and age over 18. The mean dosage of antipsychotics with and without antiparkinsonians was compared. Since there were multiple prescriptions for a given subject, generalised mixed linear models were also used to study the link between antiparkinsonian prescription and antipsychotic dosage. RESULTS: antiparkinsonians were prescribed to 32,9% of the patients. Two groups of antipsychotics were observed relating to differences in dosage when an antiparkinsonian was co prescribed or not : a first group, where the mean dosage was higher with antiparkinsonians (risperidone, amisulpride and haloperidol) and a second group (clozapine, olanzapine), in which antiparkinsonian co prescription was not related to the dosage of antipsychotics. CONCLUSION: As a conclusion, it can be said that it is important to consider the dosage and the type of antipsychotic in the treatment of patients suffering of schizophrenia, because neurological side effects are frequent and can impair quality of life. Moreover the prescription of antiparkinsonians can lead to different side effects such anticholinergic effects. |
format | Text |
id | pubmed-2014748 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-20147482007-10-11 Antipsychotics dosage and antiparkinsonian prescriptions Acquaviva, Eric Gasquet, Isabelle Falissard, Bruno Clin Pract Epidemiol Ment Health Research BACKGROUND: To study the link between the dosage of several antipsychotics and the prescription of antiparkinsonians in an observational study. METHODS: In the context of a national naturalistic prospective observational study, a database containing all the prescriptions from 100 French psychiatrists during the year 2002 was analysed. The inclusion criteria were a diagnosis of schizophrenia or schizoaffective disorder and age over 18. The mean dosage of antipsychotics with and without antiparkinsonians was compared. Since there were multiple prescriptions for a given subject, generalised mixed linear models were also used to study the link between antiparkinsonian prescription and antipsychotic dosage. RESULTS: antiparkinsonians were prescribed to 32,9% of the patients. Two groups of antipsychotics were observed relating to differences in dosage when an antiparkinsonian was co prescribed or not : a first group, where the mean dosage was higher with antiparkinsonians (risperidone, amisulpride and haloperidol) and a second group (clozapine, olanzapine), in which antiparkinsonian co prescription was not related to the dosage of antipsychotics. CONCLUSION: As a conclusion, it can be said that it is important to consider the dosage and the type of antipsychotic in the treatment of patients suffering of schizophrenia, because neurological side effects are frequent and can impair quality of life. Moreover the prescription of antiparkinsonians can lead to different side effects such anticholinergic effects. BioMed Central 2007-09-03 /pmc/articles/PMC2014748/ /pubmed/17767708 http://dx.doi.org/10.1186/1745-0179-3-14 Text en Copyright ©2007 Acquaviva et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Acquaviva, Eric Gasquet, Isabelle Falissard, Bruno Antipsychotics dosage and antiparkinsonian prescriptions |
title | Antipsychotics dosage and antiparkinsonian prescriptions |
title_full | Antipsychotics dosage and antiparkinsonian prescriptions |
title_fullStr | Antipsychotics dosage and antiparkinsonian prescriptions |
title_full_unstemmed | Antipsychotics dosage and antiparkinsonian prescriptions |
title_short | Antipsychotics dosage and antiparkinsonian prescriptions |
title_sort | antipsychotics dosage and antiparkinsonian prescriptions |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014748/ https://www.ncbi.nlm.nih.gov/pubmed/17767708 http://dx.doi.org/10.1186/1745-0179-3-14 |
work_keys_str_mv | AT acquavivaeric antipsychoticsdosageandantiparkinsonianprescriptions AT gasquetisabelle antipsychoticsdosageandantiparkinsonianprescriptions AT falissardbruno antipsychoticsdosageandantiparkinsonianprescriptions |